Mark Vertue
Impact in
- Infectious Diseases top 2%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
Papers in
-
- COVID-19 Clinical Research Studies 7
- SARS-CoV-2 and COVID-19 Research 4
-
- interferon and immune responses 3
- Journals
- JAMA (5 papers)Nature (4 papers)The Lancet (3 papers)Human Genetics and Genomics Advances (1 paper)Human Genetics (1 paper)
- Partner nations
- United KingdomAustraliaItaly
In The Last Decade
Mark Vertue
16 papers receiving 2.3k citations
Mark Vertue's Hit Papers
Peers
Comparison fields: 5 of 121
- Infectious Diseases 978
- Applied Microbiology and Biotechnology 46
- Neurology 316
- Critical Care and Intensive Care Medicine 80
- Immunology 290
Countries citing papers authored by Mark Vertue
This map shows the geographic impact of Mark Vertue's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Vertue with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Vertue more than expected).
Fields of papers citing papers by Mark Vertue
This network shows the impact of papers produced by Mark Vertue. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Vertue. The network helps show where Mark Vertue may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Mapping the human genetic architecture of COVID-19 Hit paper breakdown → | 2021 | 641 |
| 2 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 403 |
| 3 | Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial Hit paper breakdown → | 2019 | 264 |
| 4 | Whole-genome sequencing reveals host factors underlying critical COVID-19 Hit paper breakdown → | 2022 | 228 |
| 5 | 2021 | 163 | |
| 6 | GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19 Hit paper breakdown → | 2023 | 121 |
| 7 | 2022 | 104 | |
| 8 | 2022 | 99 | |
| 9 | 2021 | 70 | |
| 10 | 2022 | 69 | |
| 11 | 2023 | 56 | |
| 12 | 2023 | 45 | |
| 13 | 2023 | 34 | |
| 14 | 2022 | 25 | |
| 15 | 2021 | 24 | |
| 16 | 2024 | 8 |
About Mark Vertue
Mark Vertue is a scholar working on Infectious Diseases, Immunology, Genetics, Epidemiology and Nutrition and Dietetics, having authored 16 papers that have together received 2.4k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (7 papers), SARS-CoV-2 and COVID-19 Research (4 papers), interferon and immune responses (3 papers), Machine Learning in Bioinformatics (1 paper), Respiratory viral infections research (1 paper), Knee injuries and reconstruction techniques (1 paper), Diabetes and associated disorders (1 paper) and Vitamin C and Antioxidants Research (1 paper). The work is most often cited by research in Infectious Diseases (978 citations), Applied Microbiology and Biotechnology (46 citations), Neurology (316 citations), Critical Care and Intensive Care Medicine (80 citations) and Immunology (290 citations). Mark Vertue has collaborated with scholars based in United Kingdom, Australia and Italy. Their work appears in journals such as JAMA, Nature, The Lancet, Human Genetics and Genomics Advances and Human Genetics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.